Live

FierceBiotechRegeneron pays $37M, adds $2B in biobucks to expand CytomX pact PharmaVoiceWhen the ISS comes down, will its drug R&D be lost in space?FierceBiotechAs Akeso takes center stage at ASCO, China biotech industry cements its coming of age FierceBiotechIMU Biosciences nabs $53M funding round to ‘decode’ the immune system 10x Genomics NewsDeutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.com FierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases Endpoints NewsLilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases BioPharma DiveLilly, Ascidian link up in RNA exon editing pact CellPlant cell wall-plasma membrane attachments mediate stress resilience through cellulose synthase complexes and remorins CellExplosive cytotoxicity of ruptoblasts bridges hormone surveillance and immune defense LabiotechSurge in M&As driven by patent expirations Thermo FisherThermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate Drug Discovery - BioSpectrum Asia

FierceBiotech Jun 3, 2026

As Akeso takes center stage at ASCO, China biotech industry cements its coming of age

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a...

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvykti, and single-handedly put Chinese biotech on the global map. Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever Chinese data set to command a coveted spot on the plenary session.